To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital
| Autor: | K Sowmini, Resu Neha Reddy, Vadlakonda Sruthi, Nagur Sharone Grace |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Allergy medicine.medical_specialty Adolescent Pyridines Tertiary Care Centers Absolute eosinophil count Piperidines bepotastine Statistical significance medicine Humans Pharmacology (medical) In patient vernal keratoconjunctivitis Child Olopatadine Hydrochloride olopatadine Conjunctivitis Allergic Pharmacology business.industry Tertiary care hospital Olopatadine medicine.disease allergy Dermatology eye diseases Treatment Outcome Child Preschool Itching Bepotastine Female medicine.symptom Ophthalmic Solutions business Vernal keratoconjunctivitis medicine.drug Research Article |
| Zdroj: | Indian Journal of Pharmacology |
| ISSN: | 1998-3751 |
| Popis: | INTRODUCTION: Vernal conjunctivitis comprises 0.5% of allergic eye diseases. The study is intended to collate the effectiveness of drugs by observing the reduction in signs and symptoms. OBJECTIVES: The objective of the study is to evaluate the effectiveness and safety of olopatadine 0.1% ophthalmic drops with bepotastine besilate 1.5% ophthalmic drops in patients with vernal keratoconjunctivitis (VKC). MATERIALS AND METHODS: A randomized, open-label, comparative study conducted in Sarojini Devi Eye Hospital, Telangana. The study included 50 patients diagnosed with VKC, of which Group A and Group B were given olopatadine 0.1% ophthalmic drops and bepotastine besilate 1.5% ophthalmic drops, respectively, twice a day for 8 weeks. The reduction in signs and symptoms in both groups was compared. The observations and results were tabulated accordingly, and data were analyzed using the SPSS. The unpaired t-test is used as the test of significance in between two groups. P value is statistically significant when it is less than 0.05. RESULTS: Overall, 50 cases were included in the study, 72% of total patients were in the age group of 5–10 years, and 28% were in the age group of 11–15 years. There were 39 males and 11 females. After 8 weeks of follow-up, the mean reduction in the scoring of symptoms and signs provided better and quicker relief of watering, ocular discomfort, and conjunctival hyperemia with bepotastine 1.5% eye drops. Olopatadine 0.1% eye drops provided faster improvement in papillary hypertrophy. Both drugs were equally effective in reducing itching. Laboratory findings of absolute eosinophil count had no statistical significance in between the two groups. CONCLUSIONS: In this study, based on the evaluation of therapeutic performance, bepotastine eye drops proved quicker relief of symptoms and signs compared to olopatadine eye drops but was not statistically significant which would prove beneficial for the patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|